Pre-market Study to Evaluate Safety and Performance of GreenBone Implant (Long Bone Study)

  • End date
    Dec 24, 2022
  • participants needed
  • sponsor
    GreenBone Ortho S.r.l.
Updated on 24 January 2021


Multi-center, international, prospective, open-label, single-arm, first-in-human clinical investigation. The Patients enrolled in this clinical investigation will undergo a scheduled surgery for the treatment of long bone defects up to 6 cm using GreenBone Implant. After the surgery, the Patients will be monitored at pre-scheduled visits up to 12 months. Adverse events, pain, quality of life and functional parameters, as well as X-ray and CT scan, will be evaluated at scheduled follow-up visits. An independent Data Safety Monitoring Board (DSMB) will review the safety reports at regular intervals and Serious Adverse Events (SAE) as soon as reported, to protect Patients participating in the study. The initial phase of the study contemplates the treatment of bone defects up to 3 cm. An adaptive interim analysis will be performed when the first 7 Patients will have completed the 6-month follow-up visit. The DSMB will review the results of the interim analysis with respect to the primary endpoint (safety), and provide one of the following recommendations to the Sponsor: a) to stop the study for unacceptable frequency and severity of adverse events or b) to continue the study up to 25 Patients recruited and to include at least 5 Patients with a longer bone defect (> 3 cm up to 6 cm).


This is a pre-market multi-centre, international, open label, single-arm, study to evaluate the safety and performance of a Class III medical device (GreenBone Implant) for the treatment of long bone defect. Bone defects can result from malformation, high-energy traumatic events, bone resection due to different pathologies such as tumors or infections, or from the treatment of complex non-unions. Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. These types of treatment carry the risk of transferring disease from animals and/or humans to the patient; there is also a risk of host local allergic reaction. Bone substitutes are devoid of the above risks and therefore they could be used alternatively to xenografts and allografts. GreenBone is a ceramic resorbable bone scaffold that has very similar structure to bone. It can be produced in large quantities, shaped easily and sterilised without losing its properties. Consequently, it is an ideal substitute that could be used to fill bone defects. This study will assess the safety of using GreenBone treatment of long bone defects up to 6 cm. Moreover it will assess its capacity of promoting new bone formation. The investigators will recruit 25 patients with long bone defect and instead of bovine xenograft we will use the GreenBone implant for the long bone reconstruction. Patients will be followed up for 12 months in total.

Condition Bone Substitutes, Bone Defect
Treatment surgical repair of long bone defects
Clinical Study IdentifierNCT03884790
SponsorGreenBone Ortho S.r.l.
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

Male or female Patients
Patients aged 18 and 65 years old
Patients requiring long bone defect reconstructions up to 3 cm, resulting from high-energy traumatic events, or from the treatment of complex bone non-unions in the extremities (arms and legs), or patients undergoing the second stage of the Masquelet technique
Patients understanding the nature of the study and providing their informed consent to participation
Patients willing and able to attend the follow-up visits and procedures foreseen by study protocol
Please note: after interim analysis review by the DSMB, inclusion criteria n
will be modified as follows (all Investigators will be notified by the
Sponsor, and adequate training by Clinical Research Associate-CRA will be
Change of inclusion criteria n. 3: Patients requiring long bone defect
reconstructions longer than 3 cm and up to 6 cm, resulting from high-energy
traumatic events, or from the treatment of complex bone non-unions in the
extremities (arms and legs), or patients undergoing the second stage of the
Masquelet technique

Exclusion Criteria

Patients with bone infection at the time of enrolment
Patients with bone malignant tumor(s) at the time of enrolment
Patients who have been treated with chemotherapy or radiotherapy within 12 months before the enrolment
Patients with concomitant infectious systemic diseases at the time of enrolment
Patients with known inflammatory systemic diseases at the time of enrolment
Patients with concomitant myeloproliferative disorders at the time of enrolment
Patients currently treated with systemic immunosuppressive agents, excluding steroids
Patients with active autoimmune disease
Patients with a pre-existing calcium metabolism disorder (i.e. hypercalcemia)
Known hyperthyroidism or autonomous thyroid adenoma
Patients with coagulopathy or bleeding disorders
Patients who are not allowed to undergo the study procedures involving imaging (X-rays, CT scan) based on Investigator's judgement
Patients with known or suspected allergy or hypersensitivity to the GreenBone Implant components
Patients who are participating or have participated in other clinical studies within the 30 days before the study enrolment
Patients identified by the Investigator to have intra-operative findings that may preclude conduct of study procedure
Patients with occurrence of major intra-operative complications that require resuscitation or deviation from the planned surgical procedure
Women who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical investigation and for three months later
Female Patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note